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Treatments which heighten the immune response can inhibit tumor growth in
susceptible hosts. For example, BCG administered with tumor cells or injected into
established intradermal tumors (1, 2) resulted in specific, systemic tumor immunity
in guinea pigs. These procedures, however, depended upon direct contact of BCG
and tumor cells; contralateral challenges were less effective (3). Another approach,
effective with cutaneous neoplasms, involved the use of sensitizing agents such as
dinitrochlorobenzene (DNCB) or purified protein derivative (PPD) of tuberculin
(4). Such agents elicited delayed hypersensitivity reactions (cellular immunity)
at sites of neoplastic lesions, followed by regression and reduced incidence of new
lesions. This form of local sensitization therapy, however, requires prior identifica-
tion of superficial neoplastic lesions, and might not generate systemic tumor im-
munity if applied some distance away from tumor cells.
In mice, alloantigenic tumor cells stimulating a host rejection response have
provided protection against other tumor cells to which the untreated hosts are sus-
ceptible (5, 6). In the latter study, alloantigenic (B16) melanoma implantation
preceded by one week the contralateral challenge by Harding-Passey (H-P) mela-
noma to H-P-susceptible BALB/c mice, resulting in an induced systemic immunity
against the H-P melanoma. But, not every H-P-challenged BALB/c recipient was
adequately protected by the alloantigenic B16 melanoma pretreatment. Only 40%
rejected their H-P implants, about 30% exhibited retarded H-P growth, and 30%
indicated no anti-H-P protection when compared with untreated control hosts. We
have, therefore, sought, and found, more effective protection in the form of strongly
alloantigenic normal tissue implants, i.e., spleen and liver cells. Moreover, the use
of more precisely genetically controlled antigenic variants found in various inbred
mouse strains has led to results tending to rule out explanations of induced tumor
rejection due to cross-reactions. Our findings are consistent with the possible ad-
juvant effect of alloantigenic tissue implants leading to augmentation of an other-
wise inadequate tumor immunity. Finally, the results indicate that the induced
tumor immunity is systematic and persistent.
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MATERIALS AND METHODS
Mice. Our most extensively used test system consisted of the highly susceptible
recipient strain, BALB/c (H-2d); the transplantable Harding-Passey melanoma;
and strain C57BL/6 (H-2b) donors of normal spleen and liver. A preliminary
experiment involved the congenic strains A/J (H-2a) and ABY (H-2b), serving,
respectively, as normal tissue donor strain and as tissue and melanoma-recipient
strain. These congenic strains have been bred so as to be identical for all histocom-
patibility factors, except for the H-2 difference.
Preimmunization. One donor spleen was minced in 0.2 ml of Tissue Culture
Medium 199 (Difco), drawn into a syringe and implanted subcutaneously into
a like-sexed H-P-susceptible recipient. The same donor's liver (without the gall-
bladder), providing three to four preimmunizing doses, was minced in 0.4 ml of
Medium 199 before subcutaneous implantation into like-sexed recipients.
Tumor challenge. H-P melanoma minces were prepared without any added mate-
rials. Subcutaneous implants of 0.06 ml minced tumor resulted in practically 100%
takes in unprotected control BALB/c hosts. When the hosts were pretreated with
normal tissue implants, the melanoma challenges were administered contralaterally
either on the same day or 1 week later. In one preliminary trial, contralateral tumor
challenge followed allogeneic liver implantation by 1 month. Xenogeneic spleen
and liver implants, obtained from deer mice (Peromyscus maniculatus), were also
tested for antitumor protection. Finally, second and third tumor challenges were
performed contralaterally to the previous tumor challenge sites.
Controls. Two types of controls were used: (1) untreated individuals, challenged
by tumor only, and (2) syngeneic (i.e., BALB/c) spleen or liver implantation
followed by contralateral tumor challenge. Whenever possible, littermates were as-
signed to both experimental and control treatment groups.
Treatment effects. Tumor size was estimated by the product of externally mea-
sured greatest and least diameters (in mm2). Complete tumor rejection was con-
cluded when no recurrence was noted 2-4 weeks after disappearance of all external
signs of tumor presence. Tumor growth retardation was scored when the tumors
of the pretreated experimental host animals exhibited at least a 2-week delay in
achieving progressive growth when compared with the slowest growing tumors in
the corresponding control groups.
Persistence of tumor immunity. The time interval between the disappearance of
a previous tumor and the challenge by another tumor provided a measure of per-
sistence of tumor immunity.
RESULTS
Antitumor protection of BALB/c hosts by C57BL/6 allografts is demonstrated
in Table 1. The following points are noteworthy:
1. All (28) untreated controls succumbed to progressive tumor growth.
2. All (11) syngeneic (BALB/c) spleen or liver pretreated controls exhibited
no antitumor protection.
3. All (6) allogeneic (C57BL/6) tissue pretreated hosts succumbed like un-
treated controls when tissue implants and tumor challenges were performed on
the same day.
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TABLE, I
ANTIiTumoit 1ROTECTION By ALLOGENEIIC TRANSPLANTS
(H1-2 anI iion-II1-2 (iffereiwees)
'I'otal
Like (lifterelit
Trieatmiienit coiitrols Retallde(ll Rejeeted iii(ividuals
1 Iniitireated BALB/c coiitrols (takes) 28 9x - - x8
A tl = 1 week
9 Syngenieic spleeni (BALB/c) 6/6 - t6
t3 Syngeineic liver (BALB/c) 5/5 5
4 Allogeneic spleeni (C57BL/6)
1st H-P challleinge 19/192 19
9nd 11-P challenige 4/1 H 8/19
3r(l H-P clmalletnge 5/5
5 Allogenieic liver (C57BL/6)
1st H-P challeiige - 1/8 7/8 8
2-nd H-P chiallenige 1/7 6/7
3-rd IL-P challemige - 91/92
A t = 0 (lays
6 Syngenieic spleen (/S - 8
7 Allogeneic spleeni 1/1
8 Allogenteic liver 5/5
A t = 1 month
9 Sytngeneic liver 1/1 - 2
10 Allogerneic liver ?1/1?
T'otal (69
a A t = interval betweeni niormal tissue graft andi conitralateral ttniomo challelnge.
4. A 1-week interval between allograft implantation and tumor challenge re-
sulted in significant antitumor protection. All (12) spleen recipients rejected their
first challenge tumors. When subsequently rechallenged, 8/12 hosts rejected a sec-
ond time, while the 4/12 hosts succumbing to their second tumors exhibited tumor
growth retardation. Five of the eight second-challenge survivors were then chal-
lenged a third time. All (5/5) rejected their third challenge tumors.
5. Comparable antitumor protection was provided by liver allografts. All but
one (7/8) hosts rejected their first challenge tumors. However, the tumor growing
progressively exhibited retarded growth. The seven survivors were rechallenged,
and all but one (6/7) rejected their second challenge tumors. Again, the single
tumor escaping the host defenses exhibited retarded growth. Two of the six sec-
ond-challenge survivors were challenged yet a third time. Both rejected their third
tumors.
6. In a preliminary test involving one untreated control, one syngeneic liver con-
trol, and one allogeneic liver experimental animal, with tumor challenges performed
1 month after pretreatments, the tumor in the allogeneic liver pretreated host grew
more slowly than did the tumors in the other hosts. This preliminary result, which
must be verified with greater numbers of tested individuals, suggests the possible
persistence of some antitumor protection after allogeneic implantation.
Clearly these treatments have induced a strong and systemic antitumor im-
munity. This immunity is also persistent as indicated in Table 4. Allogenic spleen
recipients challenged a second time as long as 81 days after first tumor disappear-
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TABLE 2
ANTITUMOR PROTECTION BY ALLOGENEIC TRANSPLANTS
(H1-2 difference only)
Total
Like different
Treatment controls Retarded Rejected individuals
Untreated A.BY controls (takes) 5 2 7
A t = 1 week
Allogeneic spleen (A/J)
1st H-P challenge - 2/2 2
2nd H-P challenge - - 2/2
Allogeneic liver (A/J)
1st H-P challenge - 5/5 5
2nd H-P challenge - 5/5
Total 14
TABLE 3
ANTITUMOR PROTECTION BY XENOGENEIC TRANSPLANTS
Total
Like different
Treatment controls Retarded No take individuals
1 Untreated BALB/c controls 7/8 1/8 8
(takes)
A t = 1 week
2 Xenogeneica spleen 2/2 2
3 Xenogeneic liver 8/6 2/6 1/6 6
Total 16
a Xenogeneic donor:Peromyscu3 maniculatus (deer mouse).
ance, and challenged a third time as long as 88 days after second tumor disap-
pearance, were still capable of tumor rejection. Similar results were obtained with
allogeneic liver. A second challenge tumor implanted 85 days after first tumor dis-
appearance exhibited retarded growth. In the 6/7 second tumor rejections, re-
cipients challenged as long as 102 days after first tumor rejection still exhibited
strong tumor immunity. Finally, in the case of the third tumor rejections, strong
tumor immunity persisted in one case for at least 46 days, and at least 73 days
in the other.
Preliminary studies with another test system, involving the congenic A/J donor
and A.BY recipient strains corroborate the results of the C57BL/6 donor and
BALB/c recipient system (Table 2). The A.BY strain seems somewhat more re-
sistant to Harding-Passey implants than BALB/c, at both the basal level of un-
treated controls and at the augmented level induced by allografts. While the
C57BL/6 and BALB/c strains differ at both H-2 and non-H-2 gene loci, the con-
genic A/J and A.BY presumably differ only at the H-2 locus. This single difference
is sufficient to induce strong, systemic tumor immunity.
Antitumor protection provided by Peromyscus xenografts (Table 3) appears to
be decidedly weaker than allograft protection. Preliminary tests still in progress
already indicate that half (3/6) of the tumors in xenogeneic liver recipients
(BALB/c hosts) grow as quickly as the tumors in untreated control hosts.
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TABLE 4
PERSISTENCE OF ANTITUMOR IMMUNITY
Treatment A t, (days)a A t2 (days)b
Range Mean Range Mean
Allogeneic spleen
Retarded takes (4/12) 7-81 44.8
Rejections (8/112) 7-81 24.5
Rejections (5/5) - 78-88 83.92
Allogeneic liver
Retarded take (1/7) 85
Rejections (6/7) 20-102 45.7
Rejections (2/2) - - 46,73 59.5
a t1 = Interval between no sign of first tumor and second tumor challenge.
A A t2 = Interval between no sign of second tumor and third tumor challenge.
DISCUSSION
Our current and previous results (6) suggest four levels of induced antitumor
immunity in the following descending order of pretreatment effects: (1) allograft,
(2) allogeneic tumor, (3) xenograft, and (4) syngeneic tissue, equivalent to un-
treated control. The reasons for these different levels of augmented tumor immunity
are not clear. Nevertheless, our testing procedure has provided a sufficiently
sensitive in vivo assay system to distinguish among several different levels of effect
with respect to induced antitumor immunity.
Our double tumor challenge system (6) was consistent with the hypothesis that
induced rejection of Harding-Passey melanoma by BALB/c hosts resulting from
allogeneic B16 melanoma implantation might be due to host cross-reaction to weak
tumor-associated cell surface antigens in both B16 and H-P tumors. Such an ex-
plantation could not be invoked to account for protection by normal allografts.
However, in the C57BL/6-BALB/c donor-recipient system it was still possible
to postulate that the C57BL/6 allografts provoke strong cross-reactive responses
to weak antigens common to both C57BL/6 spleen or liver and Harding-Passey
melanoma, but not present in the BALB/c host strain. Such an explanation cannot
hold in the case of the congenic A/J-A.BY donor-recipient system, since these
strains presumably differ only at the H-2 locus. Therefore, they cannot differ by
weak non-H-2 antigens, and hence provide no basis for cross-reactive tumor rejec-
tion. The simplest explanation of our results to date is that the incompatible grafts
constitute immunogenic stimuli which simply augment the level of cell-mediated
antitumor immunity directed against tumor-specific antigens. Thus, this form of
immunologic intervention assists the host by augmenting the level of antitumor
activity from an ineffective level to an effective one.
It may be argued that normal allogeneic spleen transplants provide adoptive anti-
tumor immunity rather than augment the host's own antitumor activity. In reply
it might first be noted that liver allografts are about as effective as normal spleen
allografts, although it might be expected that spleen should be more effective due
to a greater number of presumptive "killer" cells. Second, both spleen and liver
allografts, if they provide adoptive immunity, should exert maximum tumor-reject-
ing activity when implanted with tumor on the same day, before these allografts
are themselves rejected by the host. Just the reverse is observed; no antitumor
effect when allografts and tumor challenges occur on the same day, but rather an
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optimal effect when tumor challenge follows allograft by a week, by which time
allogeneic "killer" cells might themselves be rejected by an immunologically com-
petent host.
Finally, we have not yet observed gross indications of severe stress associated
with allogeneic implants and successive tumor challenges. It is now 10 months since
the five spleen-pretreated, three-time tumor rejecting hosts received their allografts,
and they are still alive and apparently well. In this case the cure is better than
the disease.
SUMMARY
1. Strong, systemic and persistent antitumor immunity has been induced in sus-
ceptible individuals by administering strongly alloantigenic normal tissue, spleen
or liver, prior to contralateral tumor challenge.
2. Two inbred mouse donor-recipient combinations were used: C57BL/6 allo-
grafts into BALB/c recipients, and A/J donors with congenic A.BY recipients.
Both recipient strains are highly susceptible to the Harding-Passey (H-P)
melanoma.
3. Allograft recipients, when challenged 1 week later by contralateral implanta-
tion of H-P melanoma nearly always rejected their first tumor challenges.
4. Persistence of antitumor immunity was indicated by rejections of second
tumor challenges made as long as 102 days after previous tumor disappearance,
and by rejections of third challenge tumors implanted as long as 88 days after
previous tumor disappearance.
5. Xenografts from the deer mouse, Peromyscus maniculatus, resulted in aug-
mented tumor immunity, but such grafts were not as effective as allografts.
6. Syngeneic tissue implants, or allografts performed on the same day as the
tumor challenge provided no significant antitumor protection.
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